Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.32 |
| ▸ | FASN | P49327 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL74038 | 0.76 | — | — | |
| SCHEMBL5279461 | 0.75 | ALOX15 (0.42) | — | |
| SCHEMBL921952 | 0.74 | — | — | |
| SCHEMBL921631 | 0.73 | MAOB (0.42) | — | |
| SCHEMBL2926028 | 0.72 | HDAC3 (0.41) | SLC6A3 | |
| SCHEMBL3744743 | 0.72 | CTRB1 (0.35) | SLC6A2SLC6A4SLC6A3CTRB1FASN | |
| SCHEMBL5754991 | 0.72 | TAAR1 (0.39) | SLC6A2SLC6A4SLC6A3CTRB1FASN | |
| SCHEMBL3972137 | 0.72 | CTRB1 (0.35) | CTRB1FASN | |
| SCHEMBL746094 | 0.72 | CTRB1 (0.35) | CTRB1FASN | |
| SCHEMBL633468 | 0.71 | DDB1 (0.37) | CTRB1FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737160-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2010-06-15 | — | — | US | disclosed |
| EP-1648905-B1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LAB (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBVIE INC. | 2007-07-05 | — | — | US | disclosed |
| US-7202363-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | SLC6A2 2412/4885SLC6A4 2239/4885SLC6A3 2384/4885 |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABL1, ERBB2, LCK | SLC6A2 2412/4885SLC6A4 2239/4885SLC6A3 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.